The combined treatment of acute promyelocytic leukemia (APL) cells with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) has been shown to rely on the degradation of Nucleophosmin 1 (NPM1) by proteasomes. Here, NPM1 is linked to acute promyelocytic leukemia.